Effect of Empagliflozin on Cardiac Function, Adiposity and Diffuse Fibrosis in Patients with Type 2 Diabetic Mellitus
碩士 === 國立臺灣大學 === 臨床醫學研究所 === 107 === Introduction: Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves the cardiovascular outcomes in diabetic patients. However, the mechanism is still unclear. We hypothesized that empagliflozin might have beneficial effects on...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2019
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/fg849c |